← Back to all trials
Withdrawn
NCT07532408
Romiplostim N01 in the Treatment of Refractory Chemoradiotherapy-induced AA
Conditions: Aplastic Anemia
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: PHASE2
Sponsor: Peking Union Medical College Hospital
Summary
This study aimed to explore the efficacy and safety of romiplostim N01 in the treatment of relapsed/refractory chemoradiotherapy-induced aplastic anemia
Eligibility Criteria
Inclusion Criteria:
1. Age ≥ 18 years old;
2. Diagnosed with relapsed/refractory chemoradiotherapy-induced aplastic anemia (AA). Relapsed/ refractory was defined as patients who had no response to at least 3 months of cyclosporine or thrombopoietin receptor agonists (TPO-RAs) such as eltrombopag;
3. At least one of the following conditions must be met: hemoglobin \< 90 g/L, platelet count \< 30×109/L, neutrophil count \< 1.0×109/L;
4. With baseline liver and kidney functions \
Source: ClinicalTrials.gov (NCT07532408). StuddyBuddy aggregates publicly available trial information.
